SV-102

**SV-102** is an investigational intratumoral fixed-dose, multi-target immunotherapy developed by Syncromune for metastatic castration-resistant prostate cancer. The drug comprises four active components: an anti-PD-1 monoclonal antibody, an anti-CTLA-4 monoclonal antibody, a CD40 agonist monoclonal antibody, and a CpG oligodeoxynucleotide TLR9 agonist. In the SYNC-T treatment approach, SV-102 is infused directly into a partially cryoablated tumor to combine locally released patient-specific tumor antigens with checkpoint blockade and innate and adaptive immune stimulation, with the aim of generating a systemic antitumor T-cell response. SV-102 has FDA Fast Track designation for metastatic castration-resistant prostate cancer and is being evaluated in the Phase 2 LEGION-100 study. ([syncromune.com](https://syncromune.com/2024/07/01/syncromune-granted-fda-fast-track-designation-for-sync-t-sv-102-for-the-treatment-of-metastatic-castrate-resistant-prostate-cancer-mcrpc/))

Brand names

SYNC-T

Other names

SYNC-TSYNC-T SV-102SYNC-T TherapySYNC-T Therapy SV-102